TY - JOUR T1 - Predictors of mortality in hospitalized COVID-19 patients in Athens, Greece JF - medRxiv DO - 10.1101/2020.10.12.20211193 SP - 2020.10.12.20211193 AU - Dimitrios Giannoglou AU - Evangelia Meimeti AU - Xenia Provatopoulou AU - Konstantinos Stathopoulos AU - Ioannis –Kriton Roukas AU - Petros Galanis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/14/2020.10.12.20211193.abstract N2 - Background The epidemic of COVID-19 has rapidly spread worldwide, with millions of confirmed cases and related deaths. Numerous efforts are being made to clarify how the infection progresses and potential factors associated with disease severity and mortality. We investigated the mortality in Greek hospitalized COVID-19 patients and also the predictors of this mortality.Methods Study population included 512 COVID-19 patients admitted to the hospitals of the Attica region of Greece. Patients’ demographic characteristics, comorbidities, allergies, previous vaccination for seasonal influenza virus, admission to ICU, intubation, and death were recorded. Potential predictors of in-hospital mortality were identified by regression analysis.Results The mean age of hospitalized patients was 60.4 years, and was higher in patients who deceased. The most common comorbidities were respiratory diseases, hypertension, gastrointestinal disorders, dyslipidemia, mental health diseases, asthma, diabetes mellitus and cardiovascular diseases. The need for ICU care and intubation was significantly higher among patients who died. The mortality rate was 15.8% (81 out of 512). Age ≥65 years, cancer, chronic kidney disease, endocrine diseases, central nervous system disorders, anemia, and intubation were independently associated with increased in-hospital mortality, while allergies and previous influenza vaccination were associated with decreased in-hospital mortality.Conclusion Our finding of a beneficial effect of allergies and influenza vaccination against COVID-19 infection merits further investigation, as it may shed light in the mechanisms underlying disease progression and severity. Most importantly, it may assist in the implementation of efficient protective measures and public healthcare policies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialData were provided by the 1st Regional Health Authority of Attica, following the approval of the protocol by the Scientific Committee of the Greek Ministry of Health (27628 / 23-06-2020), ensuring legality of conduct, compliance with medical ethical standards and scientific validity.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance to the Helsinki Declaration for the ethical principles for medical research involving human subjects. Data were provided by the 1st Regional Health Authority of Attica, following the approval of the protocol by the Scientific Committee of the Greek Ministry of Health (27628 / 23-06-2020), ensuring legality of conduct, compliance with medical ethical standards and scientific validity.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request ER -